Krumholz H M, Radford M J, Wang Y, Chen J, Heiat A, Marciniak T A
Department of Medicine, Yale School of Medicine, and the Yale-New Haven Hospital Center for Outcomes Research and Evaluation, CT 06520-8025, USA.
JAMA. 1998 Aug 19;280(7):623-9. doi: 10.1001/jama.280.7.623.
Despite the importance of beta-blockers for secondary prevention after acute myocardial infarction (AMI), several studies have suggested that they are substantially underutilized, particularly in older patients.
To describe the contemporary national pattern of beta-blocker prescription at hospital discharge among patients aged 65 years or older with an AMI, to identify the most important predictors of the prescribed use of beta-blockers at discharge, and to determine the independent association between beta-blockers at discharge and mortality in clinical practice.
Retrospective cohort study using data created from medical charts and administrative files.
Acute care nongovernmental hospitals in the United States.
National cohort of 115015 eligible patients aged 65 years or older who survived hospitalization with a confirmed AMI in 1994 or 1995.
Blocker as a discharge medication and mortality in the year after discharge.
Among the 45308 patients without contraindications to beta-blockers, 22665 (50.0%) had a beta-blocker as a discharge medication. There was significant variation by state, ranging from 30.3% to 77.1 %. Of the 36795 patients who were not receiving beta-blocker therapy on admission, 16006 (43.5%) had therapy initiated on or before discharge. Demographic and clinical variables explained relatively little of the variation in the initiation of beta-blocker therapy. The prescribed use of calcium channel blockers at discharge had a strong negative association with the use of beta-blockers (odds ratio [OR] of beta-blocker use, 0.25; 95% confidence interval [CI], 0.24-0.26). The New England region had significantly higher use of beta-blocker therapy than the rest of the country. Compared with cardiologists, internists had similar rates (OR, 0.94; 95% CI, 0.90-1.00) and general and family practice physicians had lower rates (OR, 0.78; 95% CI, 0.73-0.83). After adjusting for potential confounders, beta-blockers were associated with a 14% lower risk of mortality at 1 year after discharge. The association with lower mortality was present in subgroups stratified by age, sex, and left ventricular ejection fraction.
Many ideal patients for beta-blocker therapy are not prescribed these drugs at discharge following AMI. The clinical and demographic characteristics of the patients do not explain much of the variation in the treatment pattern. Geographic factors and physician specialty are independently associated with the decision to use beta-blockers. Elderly patients who are prescribed beta-blockers at discharge have a better survival rate, consistent with the findings of randomized controlled trials of younger and lower-risk populations.
尽管β受体阻滞剂对急性心肌梗死(AMI)后的二级预防很重要,但多项研究表明,它们的使用严重不足,尤其是在老年患者中。
描述65岁及以上AMI患者出院时β受体阻滞剂的当代全国处方模式,确定出院时β受体阻滞剂处方使用的最重要预测因素,并确定临床实践中出院时使用β受体阻滞剂与死亡率之间的独立关联。
使用从病历和管理文件中创建的数据进行回顾性队列研究。
美国的非政府急症医院。
1994年或1995年确诊AMI后住院存活的115015名65岁及以上符合条件的全国队列患者。
出院时使用阻滞剂作为药物以及出院后一年内的死亡率。
在45308名无β受体阻滞剂禁忌症的患者中,22665名(50.0%)出院时使用了β受体阻滞剂。各州之间存在显著差异,范围从30.3%到77.1%。在入院时未接受β受体阻滞剂治疗的36795名患者中,16006名(43.5%)在出院时或出院前开始接受治疗。人口统计学和临床变量对β受体阻滞剂治疗开始的差异解释相对较少。出院时使用钙通道阻滞剂与β受体阻滞剂的使用呈强烈负相关(β受体阻滞剂使用的比值比[OR]为0.25;95%置信区间[CI]为0.24 - 0.26)。新英格兰地区β受体阻滞剂治疗的使用率明显高于美国其他地区。与心脏病专家相比,内科医生的使用率相似(OR为0.94;95%CI为0.90 - 1.00),普通内科和家庭医生的使用率较低(OR为0.78;95%CI为0.73 - 0.83)。在调整潜在混杂因素后,β受体阻滞剂与出院后1年死亡率降低14%相关。在按年龄、性别和左心室射血分数分层的亚组中,也存在与较低死亡率的关联。
许多适合使用β受体阻滞剂治疗的理想患者在AMI出院时未开具这些药物。患者的临床和人口统计学特征并不能很好地解释治疗模式的差异。地理因素和医生专业与使用β受体阻滞剂的决定独立相关。出院时开具β受体阻滞剂的老年患者生存率更高,这与年轻和低风险人群的随机对照试验结果一致。